Current Report Filing (8-k)
04 1월 2018 - 9:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 4, 2018
AUDENTES THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
|
001-37833
|
|
46-1606174
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
600 California Street, 17th Floor
San Francisco, California
|
|
94108
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(415)
818-1001
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or
Rule 12b-2 of
the Securities Exchange Act of 1934 (17
CFR 240.12b-2).
Emerging growth company ☒
If an emerging
grown company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 7.01.
|
Regulation FD Disclosure.
|
On January 4, 2018, Audentes Therapeutics, Inc. (the
Company) issued a press release attached hereto as Exhibit 99.1 announcing the results of data from the first interim analysis of ASPIRO patients, and the investor presentation attached hereto as Exhibit 99.2. ASPIRO is a multicenter,
multinational, open-label, ascending dose, delayed-treatment control study to evaluate the safety and preliminary efficacy of AT132 in approximately 12 XLMTM patients less than five years of age.
The information furnished with this report, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed filed for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities
Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01
|
Financial Statements and Exhibits.
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
AUDENTES THERAPEUTICS, INC.
|
|
|
By:
|
|
/s/ Thomas Soloway
|
|
|
Thomas Soloway
|
|
|
Chief Financial Officer
|
Date: January 4, 2018
Boundless Bio (NASDAQ:BOLD)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Boundless Bio (NASDAQ:BOLD)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024